Healthcare Services

Pelvic Inflammatory Disease (PID) Treatment Market Performance Outlook 2026–2030: Revenue to Hit $6.13 Billion at 5.3% CAGR

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the pelvic inflammatory disease (pid) treatment market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Pelvic Inflammatory Disease (PID) Treatment Market between 2026 and 2030?

The pelvic inflammatory disease (pid) treatment market has demonstrated significant expansion in recent years. Its value is projected to rise from $4.74 billion in 2025 to $5 billion in 2026, at a compound annual growth rate (CAGR) of 5.5%. This historical growth can be attributed to the high prevalence of sexually transmitted infections, limited awareness of PID, reliance on broad-spectrum antibiotics, delayed diagnosis due to asymptomatic cases, and insufficient access to specialized gynecological care.

The pelvic inflammatory disease (pid) treatment market is projected to experience robust expansion over the coming years, reaching a valuation of $6.13 billion by 2030, driven by a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily due to several factors, including the increasing acceptance of combination antibiotic regimens, a rise in the application of hormonal therapy for preventive measures, progress in minimally invasive surgical techniques, the proliferation of telehealth and remote monitoring options, and enhanced awareness and educational initiatives aimed at early diagnosis. Key trends emerging in this period encompass the escalating utilization of AI for prompt diagnosis and risk assessment, a rising embrace of genomics-driven personalized treatment methods, the convergence of cloud and big data for comprehensive patient surveillance and care, the deployment of IoT-enabled devices for distant symptom monitoring, and the adoption of smart manufacturing processes in the production of antibiotics.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21251&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Pelvic Inflammatory Disease (PID) Treatment Market?

The rising occurrence of sexually transmitted infections is anticipated to boost the expansion of the pelvic inflammatory disease (PID) treatment market in the future. Sexually transmitted infections (STIs) are conditions resulting from bacteria, viruses, or parasites, predominantly transmitted through sexual activities like vaginal, anal, or oral sex. The growing incidence of STIs stems from elements such as unsafe sexual practices, unprotected intercourse, insufficient knowledge, late diagnosis, and inadequate treatment. Pelvic inflammatory disease (PID) treatment plays a crucial role in addressing sexually transmitted infections (STIs) by deploying antibiotics to eradicate the pathogens, averting issues like persistent pelvic discomfort and infertility, and diminishing the likelihood of repeated infections. For instance, in October 2024, according to a report published by the UK Health Security Agency (UKHSA), a UK-based government agency, in 2023, England recorded 6,008 new human immunodeficiency virus (HIV) diagnoses, marking a 51% increase compared to the 3,975 diagnoses in 2022. Consequently, the increasing prevalence of sexually transmitted infections is fueling the growth of the pelvic inflammatory disease (PID) treatment market.

What Segments Are Included Within The Pelvic Inflammatory Disease (PID) Treatment Market?

The pelvic inflammatory disease (pid) treatment market covered in this report is segmented –

1) By Treatment Type: Antibiotic Therapy, Surgery, Pain Management

2) By Route Of Administration: Oral, Intravenous, Intramuscular

3) By End User: Hospitals, Clinics, Homecare

Subsegments:

1) By Antibiotic Therapy: Broad-spectrum Antibiotics, Combination Antibiotic Therapy, Oral Antibiotics, Intravenous Antibiotics

2) By Surgery: Laparoscopy, Hysterectomy, Tubal Surgery

3) By Pain Management: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Opioid Analgesics, Acetaminophen, Localized Pain Management

Which Trends Are Guiding The Evolution Of The Pelvic Inflammatory Disease (PID) Treatment Market?

Companies operating within the pelvic inflammatory disease (PID) treatment market are primarily concentrating on innovative formulations, including probiotic supplements, to improve treatment efficacy, re-establish vaginal microbiota balance, and decrease the recurrence of infections in individuals with pelvic inflammatory disease (PID). A probiotic supplement is a product that contains beneficial live bacteria or yeasts, designed to help sustain or restore a healthy equilibrium of gut and vaginal microbiota. For example, in November 2024, Lee Health Domain, an India-based pharmaceutical company, launched V-Ferin, a probiotic supplement intended to support vaginal health. Formulated with Lactobacillus acidophilus, lactoferrin peptide, and cranberry extract, V-Ferin seeks to restore the natural microbiome and prevent common vaginal infections such as bacterial vaginosis and yeast infections. With approximately 25-30% of women affected by these conditions, which can lead to pelvic inflammatory disease if left untreated, V-Ferin offers a novel approach to enhance health and prevent complications.

Who Are The Top-Performing Companies In The Pelvic Inflammatory Disease (PID) Treatment Market In Recent Years?

Major companies operating in the pelvic inflammatory disease (pid) treatment market are Pfizer Inc., Bayer AG, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Pharmaceuticals Inc., Torrent Pharmaceuticals Ltd., Mankind Pharma Ltd., Mayne Pharma Group Limited, Saphnix Lifesciences, Aristo Pharmaceuticals Pvt. Ltd., Zydus Cadila Healthcare Ltd., Amagen India Life Sciences

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pelvic-inflammatory-disease-pid-treatment-global-market-report

Which Region Currently Holds The Largest Share Of The Pelvic Inflammatory Disease (PID) Treatment Market?

North America was the largest region in the pelvic inflammatory disease (PID) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pelvic inflammatory disease (pid) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pelvic Inflammatory Disease (PID) Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21251&type=smp

Browse Through More Reports Similar to the Global Pelvic Inflammatory Disease (PID) Treatment Market 2026, By The Business Research Company

Chlamydia Infection Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/chlamydia-infection-treatment-global-market-report

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Uterine Fibroids Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/uterine-fibroids-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795